Search for a trial

Complement activation defects in pediatric oncology patients: hidden factors contributing to the increased risk of infection.

1: Elucidation of the factors that cause the complement deficiency in pediatric oncology patients. First, we will characterize the inhibitor of MASP-2 activity in patients during chemotherapy. 2: Identification of the complement component(s) causing…

Colonisation of highly resistant bacteria in newly hospitalized patients at the OLVG.

The percentage of HRMO Enterobacteriaceae of hospitalized patients at time of admission.

Safety and efficacy of vaccination with T cell-dependent and T cell-independent primary and recall antigens in patients with rheumatoid arthritis treated with anti TNF-* antibodies (adalimumab) or anti B cell therapy (Rituximab).

To assess the effect of adalimumab and rituximab on the safety and efficacy of vaccination with T cell-dependent and T cell-independent primary and recall antigens.